Pharmaceuticals News and Research

RSS

NPF, CORRONA to create first psoriasis registry to improve treatments and patient outcomes

To advance understanding of psoriasis—the most common autoimmune disease in the country, affecting up to 7.5 million Americans—and help scientists and clinicians improve treatments and patient outcomes, the National Psoriasis Foundation and the Consortium of Rheumatology Researchers of North America, Inc. will create the first psoriasis registry co-developed and co-administered by a nonprofit.

10 Jan 2014

Hormone associated with improved glucose metabolism activates calorie-burning brown fat

Researchers at Joslin Diabetes Center have discovered that a hormone long associated with weight loss and improved glucose metabolism is linked to activation of calorie-burning brown fat.

10 Jan 2014

Neurovance announces interim results from phase 2a pilot study of EB-1020 SR in patients with all subtypes of ADHD

Neurovance Inc. today announced interim results from its phase 2a pilot study of EB-1020 SR in adult patients with all subtypes of ADHD. With the four week trial fully enrolled and dosing completed in the majority of patients, the results indicate a statistically significant improvement in ADHD symptoms.

10 Jan 2014

Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

Synta Pharmaceuticals Corp. today announced the initiation of three multicenter, randomized trials supported by the Leukemia & Lymphoma Research Fund and Cancer Research UK, evaluating ganetespib in combination with chemotherapy in first-line treatment of patients with AML and high risk MDS.

10 Jan 2014

Akorn acquires NDA and all rights to Betimol from Santen

Akorn, Inc., a niche generic pharmaceutical company, today announced that it has acquired the NDA and all rights to Betimol (timolol ophthalmic solution) 0.25% & 0.5% from Santen. Akorn plans to begin shipping Betimol in the first quarter of 2014.

9 Jan 2014

Trevena doses first patient in TRV027 Phase 2b trial for acute heart failure

Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G-protein coupled receptor biased ligands, announced today initiation of dosing in BLAST-AHF, the Company's randomized, multi-center Phase 2b trial of TRV027 in patients with acute heart failure.

9 Jan 2014

Mylan announces launch of Mycophenolic Acid Delayed-release Tablets

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Mycophenolic Acid Delayed-release Tablets, 180 mg and 360 mg. This product is the generic version of Novartis' Myfortic Delayed-release Tablets.

9 Jan 2014

Illumina signs multi-year licensing agreement with Quest Diagnostics

Illumina, Inc. today announced it has entered into a multi-year licensing agreement with Quest Diagnostics, the world's leading provider of diagnostic information services, related to the use of Illumina's next-generation sequencing technology for clinical laboratory testing.

From Illumina, Inc. 9 Jan 2014

More standardised methods needed for extemporaneous preparation of paediatric medicines

More standardised methods are needed for the extemporaneous preparation of paediatric medicines, indicates a doctoral dissertation examined at the University of Eastern Finland. Hospital pharmacies modify adult medicines for children when there are no suitable paediatric medicines available. Medicines intended for adults can be modified for children into oral suspensions, oral powders or capsules the contents of which are emptied for use.

9 Jan 2014

Auxilium Pharmaceuticals reports interim data from XIAFLEX Phase 4 study in patients with DC

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced that interim data from its Phase 4 retreatment study (AUX-CC-862) evaluating XIAFLEX (collagenase clostridium histolyticum or CCH) in adult patients with Dupuytren's contracture and a recurrent contracture with a palpable cord will be presented for the first time at the American Association for Hand Surgery 2014 Annual Meeting being held January 8-11, 2014 in Kauai, Hawaii.

9 Jan 2014

New research unit at JGU examines extreme experiences in human life using biomedical explanations

The German Research Foundation (DFG) is establishing a new research unit at Johannes Gutenberg University Mainz (JGU). The interdisciplinary group will examine how new biomedical capabilities can lead to extreme experiences in human life.

9 Jan 2014

Proteon's PRT-201 gets orphan drug designation for prevention of arteriovenous access dysfunction

Proteon Therapeutics, Inc., a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases, today announced that its lead product, PRT-201, has received orphan drug designation in the European Union for the prevention of arteriovenous access dysfunction in hemodialysis patients.

9 Jan 2014

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company, announced today the initiation of a Phase Ib clinical trial to study the safety and efficacy of RX-3117 in cancer patients with solid tumors.

9 Jan 2014

MicroRNA biomarker shows promise in predicting treatment response of ovarian cancer

Researchers at Case Western Reserve University have identified a microRNA biomarker that shows promise in predicting treatment response in the most common form of ovarian cancer - a breakthrough that has the potential to improve outcomes for patients with the disease.

9 Jan 2014

Nociceptin in brain naturally moderates effects of stress

Collaborating scientists at The Scripps Research Institute (TSRI), the National Institutes of Health (NIH) and the University of Camerino in Italy have published new findings on a system in the brain that naturally moderates the effects of stress.

8 Jan 2014

Qosina announces addition of new Control Stroke Syringes

Qosina is pleased to announce the addition of five new Control Stroke Syringes. These syringes help ensure volume regulation during fluid delivery, and are used for precise injection or withdrawal. All syringes are equipped with a dimple inside the barrel opposite the graduation, which acts as a plunger stop.

8 Jan 2014

Forest Laboratories enters into definitive agreement to acquire Aptalis

Forest Laboratories, Inc. today announced that it has entered into a definitive agreement to acquire Aptalis, a privately held U.S. based specialty Gastrointestinal and Cystic Fibrosis company, for $2.9 billion in cash from its shareholders, including TPG, the global private investment firm. The acquisition, which requires review by anti-trust authorities in the US and Canada, is expected to be accretive to Forest's FY2015 non-GAAP EPS.

8 Jan 2014

Emmaus completes all patient visits for Phase 3 trial of L-glutamine for treatment of sickle cell disease

Emmaus Medical, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of innovative and cost-effective treatments and therapies primarily for rare and orphan diseases, today announced it has completed all patient visits for its Phase 3 clinical trial for the treatment of sickle cell disease. Emmaus expects top-line data from the Phase 3 clinical trial to be available in the first quarter of 2014.

8 Jan 2014

No added benefit from aflibercept, shows study

For the third time in one year, the German Institute for Quality and Efficiency in Health Care (IQWiG) dealt with the drug aflibercept. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the Institute now examined whether aflibercept (trade name: Eylea) offers an added benefit over the appropriate comparator therapy in visual impairment due to macular oedema following occlusion of the central retinal vein.

8 Jan 2014

FDA completes inspection of LSNE's medical device manufacturing facility in Manchester

Lyophilization Services of New England, a New Hampshire based contract manufacturing organization is pleased to announce that the Food and Drug Administration recently completed an inspection of their Manchester manufacturing facility.

8 Jan 2014

Pharmaceuticals News and Research

NPF, CORRONA to create first psoriasis registry to improve treatments and patient outcomes

Hormone associated with improved glucose metabolism activates calorie-burning brown fat

Neurovance announces interim results from phase 2a pilot study of EB-1020 SR in patients with all subtypes of ADHD

Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

Akorn acquires NDA and all rights to Betimol from Santen

Trevena doses first patient in TRV027 Phase 2b trial for acute heart failure

Mylan announces launch of Mycophenolic Acid Delayed-release Tablets

Illumina signs multi-year licensing agreement with Quest Diagnostics

More standardised methods needed for extemporaneous preparation of paediatric medicines

Auxilium Pharmaceuticals reports interim data from XIAFLEX Phase 4 study in patients with DC

New research unit at JGU examines extreme experiences in human life using biomedical explanations

Proteon's PRT-201 gets orphan drug designation for prevention of arteriovenous access dysfunction

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

MicroRNA biomarker shows promise in predicting treatment response of ovarian cancer

Nociceptin in brain naturally moderates effects of stress

Qosina announces addition of new Control Stroke Syringes

Forest Laboratories enters into definitive agreement to acquire Aptalis

Emmaus completes all patient visits for Phase 3 trial of L-glutamine for treatment of sickle cell disease

No added benefit from aflibercept, shows study

FDA completes inspection of LSNE's medical device manufacturing facility in Manchester

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence